ClinicalTrials.gg
RecruitingNCT06381453BELiefUpdated Oct 22, 2026

Belimumab in Autoimmune Hepatitis

A Phase 2 interventional study of Belimumab Auto-Injector [Benlysta] in Autoimmune Hepatitis, sponsored by University Health Network, Toronto. Recruiting at 6 sites in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 22, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression. Current therapies are limited, not targeted, and associated with side effects that patients report reduce quality of life. AIH is believed to arise as a consequence of genetic \& environmental risks. Disease is characterised by impaired immunoregulation, that favours a chronic and relapsing hepatitis. As well as recognising an important role for cytotoxic T cells and regulatory T cells, it has become apparent that in AIH, as well as other related autoimmune conditions, that B-cells are important. AIH is characterised by a plasma cell rich interface hepatitis and elevated IgG concentrations. Furthermore B-cell lineages interact with regulatory T-cells. Off-label use of Rituximab, an anti-CD20 agent, has been described for patients with AIH. A number of other ways of effectively targeting B-cells in the treatment of related autoimmune diseases have also been developed, but there have been limited studies in people living with autoimmune hepatitis. Belimumab is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator. It is approved in the Canada to treat systemic lupus erythematosus and lupus nephritis. It has not been studied before in AIH, but off-label reports are published. In an open-label clinical trial of people living with autoimmune hepatitis, the investigator will now formally study the effect of adding Belimumab to existing standard of care, with the goal being to evaluate treatment efficacy, the ability to reduce the burden of existing therapies whilst still controlling AIH disease, and to describe the tolerability \& safety of Belimumab in people with AIH. Study Design: Open label, multi-centre, Canadian clinical trial. Patient population: Patients with autoimmune hepatitis, excluding patients with decompensated liver disease, who either have active disease despite standard of care (Group A), or who are maintained with disease remission using standard of care therapy (Group B). 48 patients will be recruited. Intervention: Weekly sub-cutaneous Belimumab. Duration: 72 weeks with interim analysis after 24 patients have been treated for 24 weeks; target recruitment 48 patients. Evaluation: Safety, Serum liver tests, quality of life, exploratory immunologic biomarkers, optional liver biopsy or fine needle liver aspirate. Primary end-point: Group A: 50% or more of subjects have an ALT\<2x ULN \& corticosteroids at a dose of \</= 5mg of Prednisone (or equivalent); Group B: 50% or more of subjects able to maintain remission (normal ALT, normal IgG) on monotherapy with Belimumab. Conclusion: Using a combination of makers of treatment efficacy and safety the investigator will test the hypothesis that Belimumab should be further formally evaluated for people living with AIH.

02

Conditions studied

  • Autoimmune Hepatitis

Browse trials for

03

In context

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

This study's planned enrollment of 48 is close to the median of 48 across 42 interventional studies indexed under Hepatitis, Autoimmune.

Browse Hepatitis, Autoimmune studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written
  • Established clinical diagnosis of hepatitis for at least 6 months
  • Participant and clinician consent to follow AIH study therapy guidance for the duration of the open label clinical trial.

Group A:

  • > 1.5 x in the absence of clinical evidence or concern for alternative etiology, and assessed by the investigator as related to active AIH using standard of care evaluation.
  • Ongoing therapy with , and/or non-biologic (AZA, MMF, MP) at a stable dosage for 4 weeks prior to screening

Group B:

  • Patients with normal ALT and normal IgG concentration
  • Ongoing therapy with single agent immunosuppression or immunosuppression with low dose Prednisone (10mg or less or budesonide 6mg or less)) alongside a agent (azathioprine, MMF, MP)
  • Fibroscan showing liver stiffness of \< 16kPa.

Exclusion criteria

Exclusion Criteria:

  • Primary liver disease other than AIH
  • High probability of NAFLD as assessed by the investigator.
  • >15 x
  • Patients positive for or HBcAb and/or RNA
  • Prior use if >15mg daily
  • A positive pregnancy test and/or breast feeding
  • The presence of advanced liver disease as defined by any of:

    1. Total >3 x ULN.
    2. count \<100 x109/L.
    3. >1.5
  • within 30 days prior to screening or at any time during the study
  • The use of other biologics including TNF inhibitors, abatacept, or tocilizumab within the
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Belimumab

    200mg subcutaneous injection once a week

    Drug: Belimumab Auto-Injector [Benlysta]

Interventions

  • DrugBelimumabStudies of BelimumabBelimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector

    Also known as: Benlysta

06

What researchers measure

Primary outcomes

  1. To investigate the effect of treatment with Belimumab on AIH disease activity and corticosteroid use in the management of AIH

    Group A: Proportion of subjects achieving a response of ALT\<1.5x ULN and corticosteroids \</= 5mg of Prednisone (or equivalent) Group B: Proportion of subjects able to maintain remission (normal ALT, normal IgG) on monotherapy with Belimumab

    Time frame: Week 48

Secondary outcomes

  1. To investigate the effects of treatment with Belimumab on AIH disease activity and treatment burden

    * Proportion of subjects with ALT\<1.5x ULN and able to stop corticosteroids * Proportion of patients with normal ALT, normal IgG and able to stop both corticosteroids and Azathioprine/Mycophenolate Mofetil/6-Mercaptopurine * Proportion of patients with normal ALT, normal IgG and able to stop corticosteroids

    Time frame: Week 48, Week 72

  2. To measure the effects of treatment with Belimumab on AIH disease activity and treatment burden

    \- Time to biochemical disease relapse (ALT\>1.5xULN having reached values \<1.5x ULN)

    Time frame: Week 48, Week 72

  3. To see the effects of treatment with Belimumab on AIH disease activity and treatment burden

    * Changes in corticosteroid dose compared to baseline \>/= 50% reduction * Changes in corticosteroid dose compared to baseline (expressed as % of initial dosage)

    Time frame: Week 48, Week 72

  4. To measure the effects of Belimumab on markers of AIH disease activity

    \- Changes in serial biochemistry and IgG compared to baseline

    Time frame: Week 24, Week 48, Week 72

  5. To evaluate the effects of Belimumab on markers of AIH disease activity

    \- Changes in liver stiffness as measured by elastography compared to baseline

    Time frame: Week 24, Week 48, Week 72

  6. To outline the effects of Belimumab on Patient Reported Outcomes (PRO)

    \- Change in CLDQ domain scores from Baseline to end of treatment

    Time frame: Week 24, Week 48, Week 72

  7. To assess the effects of Belimumab on Patient Reported Outcomes (PRO)

    \- Change in Fatigue Scale domain scores from Baseline to end of treatment

    Time frame: Week 24, Week 48, Week 72

  8. To measure the effects of Belimumab on Patient Reported Outcomes (PRO)

    \- Change in SF-36 domain scores from Baseline to end of treatment

    Time frame: Week 24, Week 48, Week 72

  9. To evaluate the safety of Belimumab in patients with autoimmune hepatitis

    \- Incidence and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) from baseline to end of study.

    Time frame: Week 24, Week 48, Week 72

  10. To assess the safety of Belimumab in patients with autoimmune hepatitis

    \- Proportion of patients experiencing AE from baseline to end of study.

    Time frame: Week 24, Week 48, Week 72

  11. Safety and Tolerability

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Week 24, Week 48, Week 72

  12. To report the safety of Belimumab in patients with autoimmune hepatitis

    \- Change in suicidality score from baseline to end of study

    Time frame: Week 24, Week 48, Week 72

07

Study locations

6 of 6 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Apr 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Apr 24, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • The Ottawa General Hospital · Ottawa, Canada
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added
    Show site
    • The Ottawa General Hospital · Ottawa, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06381453
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Dec 11, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Gideon Hirschfield
Contact
BELief@uhn.ca
416 340 4800 ext. 2654
Gideon Hirschfield, MB BChir, PhD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion